These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 25239691

  • 1. Dabigatran-related coagulopathy: when can we assume the effect has "worn off"?
    Pollack CV, Levy JH, Eikelboom J, Weitz JI, Sellke FW, Huisman MV, Steiner T, Kamphuisen P, Bernstein RA.
    Am J Emerg Med; 2014 Nov; 32(11):1433-4. PubMed ID: 25239691
    [No Abstract] [Full Text] [Related]

  • 2. Good outcome after intravenous thrombolysis for acute stroke in a patient under treatment with dabigatran.
    Diogo C, Duarte J, Sobral S, Pestana P, Nzwalo H, Rita H, Sousa E Costa J.
    Am J Emerg Med; 2014 Nov; 32(11):1435.e1-2. PubMed ID: 24881517
    [Abstract] [Full Text] [Related]

  • 3. [Dabigatran in prevention of stroke in atrial fibrillation: three years of clinical application].
    Zotova IV, Zateĭshchikov DA.
    Kardiologiia; 2014 Nov; 54(2):79-85. PubMed ID: 24888206
    [No Abstract] [Full Text] [Related]

  • 4. Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran.
    Casado Naranjo I, Portilla-Cuenca JC, Jiménez Caballero PE, Calle Escobar ML, Romero Sevilla RM.
    Cerebrovasc Dis; 2011 Nov; 32(6):614-5. PubMed ID: 22133608
    [No Abstract] [Full Text] [Related]

  • 5. The importance of postapproval data for dabigatran.
    Redberg RF.
    JAMA Intern Med; 2015 Jan; 175(1):25. PubMed ID: 25365377
    [No Abstract] [Full Text] [Related]

  • 6. Dabigatran-induced acute hepatitis.
    Rochwerg B, Xenodemetropoulos T, Crowther M, Spyropoulos A.
    Clin Appl Thromb Hemost; 2012 Sep; 18(5):549-50. PubMed ID: 22962308
    [No Abstract] [Full Text] [Related]

  • 7. New era of oral anticoagulation for Japanese non-valvular atrial fibrillation patients.
    Hirano T.
    Circ J; 2014 Sep; 78(6):1317-9. PubMed ID: 24805358
    [No Abstract] [Full Text] [Related]

  • 8. Risk of major bleeding and the standard doses of dabigatran.
    Antoniazzi S, Berdaï D, Conti V, Clementi E, Salvo F.
    Eur J Intern Med; 2014 Jul; 25(6):e73-5. PubMed ID: 24629895
    [No Abstract] [Full Text] [Related]

  • 9. Proposed approach to thrombolysis in dabigatran-treated patients presenting with ischemic stroke.
    Kate M, Szkotak A, Witt A, Shuaib A, Butcher K.
    J Stroke Cerebrovasc Dis; 2014 Jul; 23(6):1351-5. PubMed ID: 24406026
    [Abstract] [Full Text] [Related]

  • 10. Diffuse alveolar hemorrhage associated with dabigatran.
    Yokoi K, Isoda K, Kimura T, Adachi T.
    Intern Med; 2012 Jul; 51(18):2667-8. PubMed ID: 22989848
    [No Abstract] [Full Text] [Related]

  • 11. Treatment of acute stroke in patients on dabigatran: a survey of US stroke specialists.
    Rybinnik I, Mullen MT, Messe S, Kasner SE, Cucchiara B.
    J Stroke Cerebrovasc Dis; 2013 Nov; 22(8):1312-6. PubMed ID: 23313461
    [Abstract] [Full Text] [Related]

  • 12. Pitfalls of the interpretation of myocardial infarction data in patients on dabigatran treatment.
    Pontillo D, Patruno N.
    J Cardiovasc Med (Hagerstown); 2015 Feb; 16(2):142. PubMed ID: 25539158
    [No Abstract] [Full Text] [Related]

  • 13. Plasma dabigatran activity one week after discontinuation despite normal renal function.
    Thachil J, Pike G, Keighley-Jones L, Nash MJ.
    Am J Med; 2013 Aug; 126(8):e5-6. PubMed ID: 23800582
    [No Abstract] [Full Text] [Related]

  • 14. Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients.
    Takeuchi S, Wada K, Nagatani K, Otani N, Osada H, Nawashiro H.
    Acta Neurochir (Wien); 2012 Jan; 154(1):87. PubMed ID: 22037979
    [No Abstract] [Full Text] [Related]

  • 15. Dosage of Dabigatran as a Risk Factor for Bleeding in Atrial Fibrillation.
    Liu S, Kim CO, Lucyk SN.
    JAMA Intern Med; 2015 Jul; 175(7):1244-5. PubMed ID: 26146920
    [No Abstract] [Full Text] [Related]

  • 16. Patient Characteristics and Risk of Bleeding With Dabigatran in Atrial Fibrillation.
    Henriksen DP, Hansen MR, Damkier P.
    JAMA Intern Med; 2015 Jul; 175(7):1245. PubMed ID: 26146921
    [No Abstract] [Full Text] [Related]

  • 17. [Exfoliative esophagitis while taking dabigatran].
    Scheppach W, Meesmann M.
    Dtsch Med Wochenschr; 2015 Apr; 140(7):515-8. PubMed ID: 25826037
    [Abstract] [Full Text] [Related]

  • 18. The Role of Selection in the Risk of Bleeding With Dabigatran in Patients With Atrial Fibrillation.
    Klil-Drori A, Azoulay L.
    JAMA Intern Med; 2015 Jul; 175(7):1243-4. PubMed ID: 26146918
    [No Abstract] [Full Text] [Related]

  • 19. [Dabigatran and risk of bleeding].
    Hasler S.
    Praxis (Bern 1994); 2015 Jan 28; 104(3):157-8. PubMed ID: 25626386
    [No Abstract] [Full Text] [Related]

  • 20. Atrial fibrillation: Risk of bleeding with dabigatran versus warfarin particularly high in CKD.
    Carney EF.
    Nat Rev Nephrol; 2015 Jan 28; 11(1):3. PubMed ID: 25421829
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.